Organon & Co. (OGN)
(Delayed Data from NYSE)
$20.29 USD
+0.13 (0.64%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $20.31 +0.02 (0.10%) 7:58 PM ET
4-Sell of 5 4
A Value F Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$20.29 USD
+0.13 (0.64%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $20.31 +0.02 (0.10%) 7:58 PM ET
4-Sell of 5 4
A Value F Growth A Momentum B VGM
Zacks News
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Is Trending Stock Organon & Co. (OGN) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should WisdomTree U.S. SmallCap Dividend ETF (DES) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DES
Is Most-Watched Stock Organon & Co. (OGN) Worth Betting on Now?
by Zacks Equity Research
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Organon (OGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Organon (OGN) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Organon (OGN) delivered earnings and revenue surprises of 5.66% and 1.13%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Product Demand Likely to Aid Organon's (OGN) Q2 Earnings
by Zacks Equity Research
Continued solid uptake of Organon's (OGN) products is expected to have driven second-quarter revenues.
Do Options Traders Know Something About Organon (OGN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Organon (OGN) stock based on the movements in the options market lately.
Seeking Clues to Organon (OGN) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Organon (OGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
Organon (OGN) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the latest trading session, Organon (OGN) closed at $21.86, marking a -1.84% move from the previous day.
Is WisdomTree U.S. SmallCap Dividend ETF (DES) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DES
Earnings Preview: Organon (OGN) Q2 Earnings Expected to Decline
by Zacks Equity Research
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
3 Medical Services Industry Stocks to Buy as Healthcare Wage Increases
by Urmimala Biswas
The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ICLR, OGN and DOCS are set to gain the most. Healthcare staffing shortages are leading to an increase in labor wages.
Stocks to Watch for a Potential Kamala Harris Presidency
by Shaun Pruitt
Let's discuss a few stocks and sectors that should be kept in mind for a potential Kamala Harris presidency as opposed to the Biden or Trump trade.
Organon (OGN) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Organon (OGN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Organon (OGN) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Organon (OGN) stood at $20.81, denoting a +0.39% change from the preceding trading day.
Organon (OGN) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the most recent trading session, Organon (OGN) closed at $19.93, indicating a -1.04% shift from the previous trading day.
Do Options Traders Know Something About Organon (OGN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Organon (OGN) stock based on the movements in the options market lately.
Organon (OGN) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the most recent trading session, Organon (OGN) closed at $20.63, indicating a -0.77% shift from the previous trading day.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Encompass Health (EHC) Gains 30% in a Year: More Room to Run?
by Zacks Equity Research
Encompass Health (EHC) is well-poised for growth on the back of sustained top-line growth, an aging U.S. population, frequent expansion initiatives and strong cash reserves.
Is Ocugen (OCGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Ocugen (OCGN) and Organon (OGN) have performed compared to their sector so far this year.
Humana's (HUM) CenterWell Expands in Louisiana With New Centers
by Zacks Equity Research
Humana's (HUM) CenterWell unit is likely to benefit from the opening of four new centers in the Baton Rouge and New Orleans areas in Louisiana, thus enhancing healthcare access for local seniors.